Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A and C conjugate vaccine (Beijing Luzhu Biotechnology)
- Development stage
- Unknown
- Lead developer
- Beijing Luzhu Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Green Bamboo MenAC conjugate vaccine is a bivalent meningococcal vaccine developed by Beijing Green Bamboo Pharmaceutical. It is designed to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A and C. The vaccine consists of purified capsular polysaccharides from these two serogroups, each covalently conjugated to a carrier protein (typically tetanus toxoid) to convert the T-independent polysaccharide antigens into T-dependent antigens. This conjugation significantly improves immunogenicity and the induction of immune memory, especially in infants and young children. The vaccine has been marketed in China since 2008 and is frequently utilized as a reference or comparator in clinical trials for newer meningococcal vaccines, such as quadrivalent (MenACYW) conjugates.
- Other names
- Green Bamboo MenAC conjugate vaccineBeijing Green Bamboo MenAC vaccineGroup A and Group C Meningococcal Polysaccharide Conjugate Vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A and C conjugate vaccine (Beijing Luzhu Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A and C conjugate vaccine (Beijing Luzhu Biotechnology).